RPMI 1640 Medium was developed by Moore and his co-workers in 1966 at Roswell Park Memorial Institute, hence the acronym RPMI. It is a modification of McCoy′s 5A Medium. This medium was formulated to support lymphoblastoid cells in suspension culture, but it has since been shown to support a wide variety of cells that are anchorage dependent. Originally intended to be used with a serum supplement, RPMI 1640 has been shown to support several cell lines in the absence of serum. It has also been widely used in fusion protocols and in the growth of hybrid cells. RPMI-1640 Medium has been used for maintaining cell line medium and serves as a medium for different cells.
TBS8063-500ML is modified with high glucose, L-glutamine, phenol red, and sodium bicarbonate without sodium pyruvate. Users can make any suitable modification based on the specific needs of different cell lines.
RELATED PRODUCTS
- MSC Medium (TBS8021)
- Hams F-12 Medium (TBS8032)
- DMEM Medium (TBS8061)
- Chondrogenic Differentiation Medium (TBS8062)
- RPMI-1604 Medium without Glucose (TBS8063GF)
Research use only.
Documents
References
1. Gu, T., Raval, R., Bashkin, Z., Zhou, C., Ko, S., Kong, N., Hong, S., Bhaskara, A., Shah, S., Joshi, A., Thellakal, S., Rim, K., Marimuthu, A., Venkatesan, S., Wang, E., Li, S., Jayabalan, A., Tao, A., Fang, Y., … Njoo, E. (2025). Synthesis, antiproliferative activity, and biological profiling of C-19 trityl and silyl ether andrographolide analogs in colon cancer and breast cancer cells. Bioorganic & Medicinal Chemistry Letters, 130163. https://doi.org/10.1016/j.bmcl.2025.130163
2. Gutti, M., Luo, J., Sharma, V., Lee, E., Desarkar, A., Raval, R., Soedarmono, A., Zhu, J., & Njoo, E. (2025, January 14). Anticancer synthetic arylsulfonamides with WNT1-modulating activity. bioRxiv. https://doi.org/10.1101/2025.01.11.632297
3. Somani, S., Menta, L., Wang-Johanning, F., Johanning, G., Hong, S., & Njoo, E. (2025, April 03). Synthesis, anticancer properties, and biological profiling of synthetic glycan analogs of proscillaridin A. bioRxiv. https://doi.org/10.1101/2025.03.31.646140
4. Somani, S., Menta, L., Wang-Johanning, F., Johanning, G., Hong, S., & Njoo, E. (2025, October 27). Synthesis, anticancer properties, and biological profiling of synthetic glycan analogs of proscillaridin A. Discover Pharmaceutical Sciences. 1, 25 (2025). https://doi.org/10.1007/s44395-025-00025-1
5. Gutti, M., Tsui, M., Yang, S., Xi, S., Luo, J., Desarkar, A., Xie, Y., Feng, M., Avadhani, U., Raghavan, S., Brierley-Green, E., Yu, E., & Njoo, E. (2025). Synthetic Derivatives of Vinpocetine as Antiproliferative Agents. Drugs and Drug Candidates, 4(4), 53. https://doi.org/10.3390/ddc4040053
6. Lo, I., Vaidya, S., Mo, A., Chia, A. Y. X., Li, K., Parvin, J., … & Njoo, E. (2025). Blue Fluorescent Siloxytecans Exhibit Potent Anticancer Activity and Enable Direct Real-Time Quantification of Intracellular Uptake. ACS Bio & Med Chem Au. https://doi.org/10.1021/acsbiomedchemau.5c00155
Research use only.
